Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive AppointmentsGlobeNewsWire • 06/09/25
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare ConferenceGlobeNewsWire • 06/04/25
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025GlobeNewsWire • 05/13/25
Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025GlobeNewsWire • 05/01/25
Lyell Immunopharma Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for LYL314 for the Treatment of Relapsed and/or Refractory Large B-Cell LymphomaGlobeNewsWire • 04/15/25
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024GlobeNewsWire • 03/11/25
Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare ConferenceGlobeNewsWire • 01/09/25
After Plunging -37.9% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)Zacks Investment Research • 12/31/24
After Plunging -31.22% in 4 Weeks, Here's Why the Trend Might Reverse for Lyell Immunopharma (LYEL)Zacks Investment Research • 12/30/24
Down -30.89% in 4 Weeks, Here's Why Lyell Immunopharma (LYEL) Looks Ripe for a TurnaroundZacks Investment Research • 12/13/24
Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual MeetingGlobeNewsWire • 12/10/24
Lyell Immunopharma (LYEL) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 11/14/24
Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 11/05/24
Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell TherapiesGlobeNewsWire • 10/24/24
Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual MeetingGlobeNewsWire • 10/04/24
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024GlobeNewsWire • 08/07/24
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion TechnologyGlobeNewsWire • 06/26/24